Quick Answer
AbCellera Biologics Inc. reported Stockholders Equity of $966.90 million for the year ending 2025.
- AbCellera Biologics Inc. showed a decrease of -8.4% in Stockholders Equity from 2024 to 2025.
- This data is from AbCellera Biologics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $83.69 million | Q2 2020: $90.89 million | Q3 2020: $89.26 million | Q1 2021: $957.12 million | Q2 2021: $967.68 million | Q3 2021: $953.40 million | Q1 2022: $1.21 billion | Q2 2022: $1.21 billion | Q3 2022: $1.25 billion | Q1 2023: $1.21 billion | Q2 2023: $1.19 billion | Q3 2023: $1.18 billion | Q1 2024: $1.13 billion | Q2 2024: $1.11 billion | Q3 2024: $1.08 billion | Q1 2025: $1.02 billion | Q2 2025: $1.01 billion | Q3 2025: $964.04 million.
- Over the full 8 years of available data (2018 to 2025), AbCellera Biologics Inc.'s Stockholders Equity has grown by 8,228.9%.
- Historical annual values: Fiscal year 2025: $966.90 million | Fiscal year 2024: $1.06 billion | Fiscal year 2023: $1.15 billion | Fiscal year 2022: $1.23 billion | Fiscal year 2021: $1.03 billion | Fiscal year 2020: $830.51 million | Fiscal year 2019: $10.25 million | Fiscal year 2018: $11.61 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: